Status:
COMPLETED
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Lead Sponsor:
Abbott Medical Devices
Conditions:
Angioplasty
Cardiovascular Disease
Eligibility:
All Genders
18+ years
Brief Summary
Abbott Vascular (AV) obtained marketing approval for the XIENCE PRIME Everolimus Eluting Coronary Stent System (XIENCE PRIME EECSS) in China from the China Food and Drug Administration (CFDA) on Augus...
Eligibility Criteria
Inclusion
- The patient must be at least 18 years of age at the time of signing the informed consent.
- The patient or his/her legally-authorized representative signs the European Commission (EC)-approved Informed Consent Form (ICF).
- Only XIENCE PRIME stent(s) is (are) implanted during the index procedure.
Exclusion
- No other exclusion criteria are specified for this study.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 9 2019
Estimated Enrollment :
2002 Patients enrolled
Trial Details
Trial ID
NCT01894152
Start Date
July 1 2013
End Date
October 9 2019
Last Update
May 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abbott Vascular
Santa Clara, California, United States, 95054